Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes

Abstract

Myelodysplastic syndrome (MDS) represents a heterogeneous group of disorders encompassing a wide range of pathologically distinct subtypes associated with different outcomes.5][6][7][8][9] The latest contribution to the task of adopting molecular features into the clinical prognostic scheme is represented by the Molecular International Prognostic Scoring System (IPSS-M), a product of the International Working Group for Prognosis in MDS (IWG-PM). 10Here, we took advantage of a large cohort of patients with MDS (n = 1281, supplemental Methods, available on the Blood website) to validate the novel IPSS-M and to compare the score with the well-established revised IPSS (IPSS-R).To present our clinical experience, we used a cohort of treated and untreated patients with MDS.Informed consent was obtained according to the protocols approved by the institutional review board of the Cleveland Clinic Foundation and in accordance with the ethical principles set forth by the Declaration of Helsinki.